Related Experiment Video
Updated: Apr 17, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody
Wassim Rahman1, Thomas Tu, Magdalena Budzinska
11 A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 2 Centenary Institute, Sydney, NSW, Australia. 3 Medsaic Pty Ltd, Suite 145, Level 1, National Innovation Centre, Australian Technology Park, Garden Street, Eveleigh, Australia. 4 School of Molecular and Microbial Biosciences, The University of Sydney, NSW, Australia. 5 Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia. 6 Collaborative Transplantation Research Group, Bosch Institute, The University of Sydney, NSW, Australia. 7 School of Mathematics and Statistics, The University of Sydney, NSW, Australia.
Insights
Predicting Hepatitis C virus (HCV) recurrence severity after liver transplant is crucial. Pre-transplant CD antigen expression on leukocytes can identify patients at risk for severe HCV recurrence, aiding clinical management.
Area of Science:
- Immunology
- Hepatology
- Transplantation Science
Background:
- Hepatitis C virus (HCV) reinfection post-liver transplant is common, with variable disease severity.
- Predictive markers for severe HCV recurrence are needed to guide patient management.
- Cluster of differentiation (CD) microarrays offer a potential tool for predicting recurrence severity.
Purpose of the Study:
- To investigate the utility of circulating leukocyte CD antigen expression in predicting the severity of HCV recurrence after liver transplantation.
- To identify specific CD antigens that correlate with mild or severe HCV recurrence.
Main Methods:
- Peripheral blood leukocytes from 16 liver transplant recipients were analyzed using CD antibody microarrays at various post-transplant time points (pre-transplant, early, mid, late).
- HCV recurrence severity was categorized based on fibrosis stages (F0-1 mild, F2-4 severe) within 2 years post-transplant.
- Differential expression of CD antigens was compared between patients with mild versus severe HCV recurrence.
Main Results:
- Significantly more CD antigens showed differential expression in pre-transplant samples compared to post-transplant samples.
- Five pre-transplant CD antigens (CD27 PH, CD182, CD260, CD41, CD34) were significantly associated with severe HCV recurrence.
- CD152 expression was significant in the late post-transplant phase, but pre-transplant markers were more predictive.
Conclusions:
- Circulating leukocyte CD antigen expression is a valuable tool for assessing the severity of HCV recurrence post-liver transplantation.
- Pre-transplant CD antigen profiles are the most potent predictors of HCV recurrence severity.
- This study provides a proof of principle for using CD antigen expression as a predictive biomarker.
Background:
Hepatitis C virus (HCV) reinfection of the liver allograft after transplantation is universal, with some individuals suffering severe disease recurrence. Predictive markers of recurrent disease severity are urgently needed. In this study, we used a cluster of differentiation (CD) microarray to predict the severity of HCV recurrence after transplantation.
Methods:
The CD antibody microarray assays of live leukocytes were performed on peripheral blood taken in the first year after transplantation. The results were grouped into phases defined as; Pre-transplant (day 0), Early (day 3 to week 2), Mid (week 4 to week 10), and Late (week 12 to week 26). Hepatitis C virus severity was based on fibrosis stages in the first 2 years (F0-1 mild and F2-4 severe).
Results:
Serial blood samples from 16 patients were taken before and after liver transplantation. A total of 98 assays were performed. Follow-up was 3 years or longer. Comparing recurrence severity, significantly greater numbers of CD antigens were differentially expressed on the pretransplant samples compared to any posttransplant timepoints. Five differentially expressed CD antigens before transplantation (CD27 PH, CD182, CD260, CD41, and CD34) were significantly expressed comparing severe to mild recurrence, whereas expression of only CD152 was significant in the late phase after transplantation. No relationship was observed between the donor or recipient interleukin-28B genotypes and HCV recurrence severity.
Conclusions:
This study shows that circulating leukocyte CD antigen expression has utility in assessing recurrent HCV disease severity after liver transplantation and serves as a proof of principle. Importantly, pretransplant CD antigen expression is most predictive of disease outcome.
